查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1519769

2024-2032 年囊性纖維化治療市場報告（依藥物類別、藥物分子類型、給藥途徑、最終使用者和地區）

Cystic Fibrosis Therapeutics Market Report by Drug Class, Drug Molecule Type, Route of Administration, End-User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球囊性纖維化治療市場規模達到 72 億美元。囊性纖維化盛行率不斷上升，個人對基於遺傳因素的個人化治療方法的偏好不斷增加，以及基因療法最新進展的廣泛利用是推動市場成長的一些主要因素。

囊性纖維化治療可以控制影響呼吸和消化系統的遺傳性疾病的症狀。它涵蓋一系列藥物，包括 CFTR 調節劑和基因療法，提供量身定做的治療方案。它透過增強 CFTR 蛋白的功能來幫助糾正導致 CF 的潛在遺傳缺陷。它透過控制症狀和減緩疾病進展來提高生活品質。它可以增強肺功能，幫助 CF 患者更輕鬆地呼吸並減輕呼吸道症狀。

個人對基於遺傳因素的個人化治療方法的日益偏好正在加強市場的成長。除此之外，各國政府紛紛推出針對CF研究和治療開發的政策和資金，這為CF的研究和治療開發提供了良好的市場前景。此外，對孤兒藥開發的監管激勵措施不斷加強，正在鼓勵製藥公司投資 CF 療法。此外，製藥公司、研究機構和醫療保健提供者之間不斷加強的合作正在加速新療法的開發。此外，穿戴式裝置和遠距醫療等技術的廣泛使用正在增強患者監測和治療服務。

囊性纖維化治療市場趨勢/促進因素：

CFTR 調變器的進步

CFTR調節藥物的開發和持續改進是促進市場成長的主要因素之一。這些藥物直接針對有缺陷的 CFTR 蛋白，這是 CF 患者產生濃稠黏液和隨後出現健康併發症的原因。除此之外，製藥公司不斷投資於研發 (R&D) 活動，以推出新一代 CFTR 調節劑，以提供更高的有效性和更廣泛的適用性。這些進步提供了更全面的解決方案並改善了個人的整體福祉。它們還支持改善特定 CF 患者群體的黏液清除、減少呼吸道症狀和增強肺功能。

基因療法的發展

基因療法的發展是促進市場成長的另一個主要因素。這些創新療法透過將有缺陷的 CFTR 基因的功能性拷貝引入受影響的細胞中，幫助解決 CF 的根本原因，並促進 CF 的治癒或長期管理。此外，基因療法最新進展的使用不斷增加，例如 Kaftrio 和 Trikafta 等基於基因的治療方法已被批准用於治療 CF 症狀，這提供了良好的市場前景。除此之外，基因療法的發展正在加強市場的成長。這些療法有助於提供更有效和更有針對性的治療，擴大治療選擇，並促進對潛在治療方法的研究。

增加盛行率和早期診斷

由於多種因素，CF 盛行率不斷上升，特別是在千禧世代人群中，正在推動對治療藥物的需求。同時，診斷能力的提高正在創造積極的市場前景。此外，醫療保健系統越來越擅長透過新生兒篩檢計劃和基因檢測來識別 CF 病例。除此之外，早期診斷可以在更年輕的時候開始治療，這可以顯著影響疾病進展並改善長期結果。此外，基因檢測和新生兒篩檢計畫的持續進步使得嬰幼兒 CF 的診斷變得更快、更可靠。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球囊性纖維化治療市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依藥物類別

  • 胰酵素補充劑
    • 市場走向
    • 市場預測
  • 黏液溶解劑
    • 市場走向
    • 市場預測
  • 支氣管擴張劑
    • 市場走向
    • 市場預測
  • CFTR 調變器
    • 市場走向
    • 市場預測
  • 抗生素
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依藥物分子類型

  • 小分子藥物
    • 市場走向
    • 市場預測
  • 生物製劑
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依管理途徑

  • 口服藥物
    • 市場走向
    • 市場預測
  • 吸入藥物
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按最終用戶

  • 醫院
    • 市場走向
    • 市場預測
  • 診所
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第15章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbvie Inc.
    • Alaxia
    • Alcresta Therapeutics Inc.
    • Allergan
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Vertex Pharmaceuticals Inc.
Product Code: SR112024A2117

The global cystic fibrosis therapeutics market size reached US$ 7.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 14.7 Billion by 2032, exhibiting a growth rate (CAGR) of 7.9% during 2024-2032. The rising prevalence of cystic fibrosis, increasing preferences of individuals for personalized treatment approaches based on genetic factors, and the widespread utilization of recent advancements in gene therapy are some of the major factors propelling the market growth.

Cystic fibrosis therapeutics enables management of the symptoms of a genetic disease affecting the respiratory and digestive systems. It encompasses a range of drugs, including CFTR modulators and gene therapy, offering tailored treatment options. It helps correct the underlying genetic defect responsible for CF by enhancing the function of the CFTR protein. It contributes to a better quality of life by managing symptoms and slowing disease progression. It can enhance lung function, helping individuals with CF breathe more easily and reducing respiratory symptoms.

Rising preferences of individuals for personalized treatment approaches based on genetic factors is strengthening the growth of the market. Apart from this, governing authorities of various countries are introducing policies and funding for CF research and treatment development, which is offering a favorable market outlook. Additionally, a continuous rise in regulatory incentives for orphan drug development is encouraging pharmaceutical companies to invest in CF therapeutics. Moreover, the rising collaborative efforts between pharmaceutical companies, research institutions, and healthcare providers are accelerating the development of new therapies. Furthermore, the widespread use of technology, such as wearable devices and telemedicine, is enhancing patient monitoring and treatment delivery.

Cystic Fibrosis Therapeutics Market Trends/Drivers:

Advancements in CFTR modulators

The development and continued improvement of CFTR modulator drugs represent one of the primary factors contributing to the market growth. These medications directly target the defective CFTR protein, which is responsible for the thick mucus production and subsequent health complications in individuals with CF. Apart from this, pharmaceutical companies are continuously investing in research and development (R&D) activities to introduce new generations of CFTR modulators that offer greater effectiveness and broader applicability. These advancements provide more comprehensive solutions and improve the overall well-being of individuals. They also support improved mucus clearance, reduced respiratory symptoms, and enhanced lung function in specific CF patient populations.

Development of gene-based therapies

The development of gene-based therapies is another major factor facilitating the market growth. These innovative treatments help address the root cause of CF by introducing functional copies of the defective CFTR gene into affected cells and facilitating a cure or long-term management of CF. Additionally, the rising utilization of recent advancements in gene therapy, such as the approval of gene-based treatments like Kaftrio and Trikafta for treating CF symptoms is offering a favorable market outlook. Apart from this, the evolution of gene-based therapies is strengthening the growth of the market. These therapies aid in providing more effective and targeted treatments, expanding treatment options, and fostering research into potential curative approaches.

Increasing prevalence and early diagnosis

The rising prevalence of CF, especially among the millennial population due to several factors, is driving the demand for therapeutics. Along with this, improved diagnostic capabilities are creating a positive market outlook. Additionally, healthcare systems are becoming more adept at identifying CF cases through newborn screening programs and genetic testing. Apart from this, early diagnosis allows for the initiation of treatment at a younger age, which can significantly impact disease progression and improve long-term outcomes. Furthermore, ongoing advancements in genetic testing and newborn screening programs are allowing for quicker and more reliable diagnosis of CF in infants and young children.

Cystic Fibrosis Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on drug class, drug molecule type, route of administration, and end-user.

Breakup by Drug Class:

Pancreatic Enzyme Supplements

Mucolytics

Bronchodilators

CFTR Modulators

Antibiotics

Others

CFTR modulators hold the largest market share

A detailed breakup and analysis of the market based on the drug class has also been provided in the report. This includes pancreatic enzyme supplements, mucolytics, bronchodilators, CFTR modulators, antibiotics, and others. According to the report, CFTR modulators accounted for the largest market share as they offer a highly targeted treatment approach. They address the root cause of CF at the molecular level, focusing on the defective CFTR protein. They work by improving the function of the defective CFTR protein and regulate the flow of salt and fluids in and out of cells. Additionally, the expanded approval for use in various CF patient populations, including those with specific genetic mutations drives its demand across the globe. Apart from this, pharmaceutical companies continue to invest heavily in research activities to create new generations of CFTR modulators. These efforts aim to improve the effectiveness of existing drugs and develop new ones, ensuring a competitive edge in the market.

Breakup by Drug Molecule Type:

Small Molecule Drugs

Biologics

Small molecule drugs account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug molecule type. This includes small molecule drugs and biologics. According to the report, small molecule drugs represented the largest segment as they have excellent bioavailability and get efficiently absorbed into the bloodstream after oral administration. This ensures that a significant portion of the drug reaches its target site, enhancing therapeutic efficacy. Apart from this, they are generally cost-effective to manufacture, making them attractive to pharmaceutical companies. The production processes for these drugs are well-established, allowing for economies of scale and efficient mass production. Moreover, regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established clear guidelines for the development and approval of small molecule drugs. This regulatory support ensures their safety, quality, and efficacy, bolstering confidence among healthcare professionals and patients.

Breakup by Route of Administration:

Oral Drugs

Inhaled Drugs

Oral drugs dominate the market

A detailed breakup and analysis of the market based on the route of administration has also been provided in the report. This includes oral drugs and inhaled drugs. According to the report, oral drugs accounted for the largest market share as they are often more cost-effective than other forms of medication delivery. They require less infrastructure for administration and reduce the need for healthcare professionals' involvement, leading to lower overall healthcare costs. Additionally, they do not involve needles or invasive procedures, making them more tolerable for a broader patient population. Apart from this, they are usually administered in the form of tablets or capsules, offering a level of accessibility and convenience. Apart from this, patients can take these medications easily without the need for specialized medical personnel or equipment. This convenience supports long-term treatments, chronic conditions, and self-administered therapies for several chronic diseases.

Breakup by End-User:

Hospitals

Clinics

Others

Hospitals dominate the market

The report has provided a detailed breakup and analysis of the market based on the end-user. This includes hospitals, clinics, and others. According to the report, hospitals represented the largest segment as they provide comprehensive healthcare services under one roof. They offer a wide range of medical specialties, including emergency care, surgery, radiology, pathology, and specialized clinics. Apart from this, they are primarily associated with acute care, which involves the treatment of severe and life-threatening conditions. Moreover, they are equipped with state-of-the-art medical equipment and technology. This includes advanced diagnostic tools, imaging systems, surgical robots, and intensive care units. These resources enable hospitals to deliver cutting-edge medical treatments and procedures. Furthermore, many hospitals are affiliated with medical schools and research institutions, fostering an environment of continuous learning and innovation. This research-driven approach leads to the development of new medical treatments, therapies, and best practices.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Europe leads the market, accounting for the largest cystic fibrosis therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe accounted for the largest market share since the region has a well-developed healthcare infrastructure with widespread access to medical facilities and specialized CF centers. Additionally, Europe has a relatively high prevalence of CF. This increased prevalence drives research and development (R&D) efforts as well as market demand for CF therapeutics. Apart from this, Europe is home to some of the largest pharmaceutical companies in the world. These companies invest heavily in CF therapeutics, leading to the development of innovative treatments. Furthermore, the European Medicines Agency (EMA) provides a clear regulatory pathway for the approval of CF drugs. Moreover, many European governments allocate substantial funding to support CF research and treatment. This funding accelerates the development of new therapies and promotes market growth.

Competitive Landscape:

Companies are investing heavily in research and development (R&D) activities to discover new treatments and medications that target the underlying causes of cystic fibrosis. Additionally, they are working on therapies tailored to specific genetic mutations associated with cystic fibrosis. This ensures a more effective and targeted approach to treatment. Apart from this, many companies are forming partnerships with academic institutions, research organizations, and other pharma companies to accelerate drug development and bring new therapies to market more quickly. Furthermore, they are continuously conducting and investing in phase I, II, and III clinical trials to test the efficacy and safety of new cystic fibrosis therapies.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.

Alaxia

Alcresta Therapeutics Inc.

Allergan

AstraZeneca

F. Hoffmann-La Roche Ltd.

Gilead Sciences Inc.

Merck & Co. Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

Vertex Pharmaceuticals Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Recent Developments:

In December 2022, Vertex Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration cleared its Investigational New Drug (IND) application for VX-522, a messenger ribonucleic acid (mRNA) therapy targeted at treating the underlying cause of cystic fibrosis (CF) lung disease.

In October 2020, AbbVie Inc. announced the partnership with Roche and the acquisition of the TMEM16A potentiators portfolio. The relationship influenced the expansion of the company's product line.

Key Questions Answered in This Report:

  • How has the global cystic fibrosis therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global cystic fibrosis therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global cystic fibrosis therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the drug class?
  • Which is the most attractive drug class in the cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the drug molecule type?
  • Which is the most attractive drug molecule type in the cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the route of administration?
  • Which is the most attractive route of administration in the cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the end-user?
  • Which is the most attractive end-user in the cystic fibrosis therapeutics market?
  • What is the competitive structure of the global cystic fibrosis therapeutics market?
  • Who are the key players/companies in the global cystic fibrosis therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cystic Fibrosis Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Pancreatic Enzyme Supplements
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Mucolytics
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Bronchodilators
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 CFTR Modulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Antibiotics
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Molecule Type

  • 7.1 Small Molecule Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biologics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Inhaled Drugs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbvie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Alaxia
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Alcresta Therapeutics Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Allergan
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 AstraZeneca
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche Ltd
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Gilead Sciences Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck & Co., Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novartis AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Vertex Pharmaceuticals Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cystic Fibrosis Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Cystic Fibrosis Therapeutics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Cystic Fibrosis Therapeutics Market: Breakup by Drug Class (in %), 2023
  • Figure 4: Global: Cystic Fibrosis Therapeutics Market: Breakup by Drug Molecule Type (in %), 2023
  • Figure 5: Global: Cystic Fibrosis Therapeutics Market: Breakup by Route of Administration (in %), 2023
  • Figure 6: Global: Cystic Fibrosis Therapeutics Market: Breakup by End-User (in %), 2023
  • Figure 7: Global: Cystic Fibrosis Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Cystic Fibrosis Therapeutics (Pancreatic Enzyme Supplements) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Cystic Fibrosis Therapeutics (Pancreatic Enzyme Supplements) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Cystic Fibrosis Therapeutics (Mucolytics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Cystic Fibrosis Therapeutics (Mucolytics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Cystic Fibrosis Therapeutics (Bronchodilators) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Cystic Fibrosis Therapeutics (Bronchodilators) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Cystic Fibrosis Therapeutics (CFTR Modulators) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Cystic Fibrosis Therapeutics (CFTR Modulators) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Cystic Fibrosis Therapeutics (Antibiotics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Cystic Fibrosis Therapeutics (Antibiotics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Cystic Fibrosis Therapeutics (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Cystic Fibrosis Therapeutics (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Cystic Fibrosis Therapeutics (Small Molecule Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Cystic Fibrosis Therapeutics (Small Molecule Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Cystic Fibrosis Therapeutics (Biologics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Cystic Fibrosis Therapeutics (Biologics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Cystic Fibrosis Therapeutics (Oral Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Cystic Fibrosis Therapeutics (Oral Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Cystic Fibrosis Therapeutics (Inhaled Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Cystic Fibrosis Therapeutics (Inhaled Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Cystic Fibrosis Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Cystic Fibrosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Cystic Fibrosis Therapeutics (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Cystic Fibrosis Therapeutics (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Cystic Fibrosis Therapeutics (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Cystic Fibrosis Therapeutics (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: North America: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: North America: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: United States: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: United States: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Canada: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Canada: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Asia Pacific: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Asia Pacific: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: China: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: China: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Japan: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Japan: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: India: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: India: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: South Korea: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: South Korea: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Australia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Australia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Indonesia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Indonesia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Europe: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Europe: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Germany: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Germany: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: France: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: France: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: United Kingdom: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: United Kingdom: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Italy: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Italy: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Spain: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Spain: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Russia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Russia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Latin America: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Latin America: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Brazil: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Brazil: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Mexico: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Mexico: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Middle East and Africa: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Middle East and Africa: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Global: Cystic Fibrosis Therapeutics Industry: SWOT Analysis
  • Figure 84: Global: Cystic Fibrosis Therapeutics Industry: Value Chain Analysis
  • Figure 85: Global: Cystic Fibrosis Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cystic Fibrosis Therapeutics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Drug Molecule Type (in Million US$), 2024-2032
  • Table 4: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 5: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by End-User (in Million US$), 2024-2032
  • Table 6: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Cystic Fibrosis Therapeutics Market Structure
  • Table 8: Global: Cystic Fibrosis Therapeutics Market: Key Players